Dexrazoxane
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Dexrazoxane: From Anthracycline-Induced Cardiotoxicity to Sclerosing Cholangitis
One-Sentence Summary
Dexrazoxane is a chemoprotective agent used to prevent anthracycline-induced cardiotoxicity during cancer chemotherapy, working primarily through iron chelation to reduce reactive oxygen species in cardiac tissue. The TxGNN model predicts it may be effective for Sclerosing Cholangitis, yet this prediction is currently supported by 0 clinical trials and 0 publications — representing a purely AI-driven hypothesis with no direct clinical or preclinical evidence. Across all 10 predicted indications in this Evidence Pack, cystitis (Rank 10, L4) is the only candidate with a concrete mechanistic rationale, and even that remains limited to preclinical conjecture.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Cardioprotection in patients receiving anthracycline-based chemotherapy |
| Predicted New Indication | Sclerosing Cholangitis |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| Taiwan Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Dexrazoxane is a bisdioxopiperazine compound derived from EDTA. After cellular uptake, it is hydrolyzed intracellularly to form ICRF-198, an open-chain chelator that sequesters free iron ions. By competing with anthracyclines (e.g., doxorubicin) for iron binding, it prevents the formation of anthracycline–Fe²⁺ complexes that would otherwise catalyze Fenton reactions, producing hydroxyl radicals that damage cardiomyocyte DNA and membranes. It also carries secondary Topoisomerase IIβ inhibitory activity. (Note: MOA data is listed as unavailable in the Evidence Pack; the above draws on established pharmacological literature.)
Sclerosing cholangitis — particularly Primary Sclerosing Cholangitis (PSC) — is a chronic autoimmune fibro-inflammatory disease of the bile ducts leading to progressive strictures and liver failure. Oxidative stress and iron dysregulation have been theorized to contribute to biliary epithelial injury and periductal fibrosis. On that basis, iron chelation could be imagined to reduce ROS-driven damage. However, this bridge is highly speculative: the TxGNN knowledge graph most likely identified Dexrazoxane via shared oxidative stress or immune-signalling nodes in the graph rather than a direct pharmacological pathway. There is currently no preclinical or clinical evidence of Dexrazoxane tested in any biliary disease model.
Of the 10 predicted indications reviewed, the overwhelming majority (Ranks 1–9) represent knowledge-graph noise: infections requiring antibiotics (paratyphoid fever, UTI, pyelonephritis, peritonitis, epiglottitis), mucosal conditions (conjunctivitis, laryngitis, bronchitis), and sclerosing cholangitis — none of which map to Dexrazoxane’s established mechanism. The single exception is cystitis (Rank 10): PMID 37690746 (2023) demonstrated that cyclophosphamide metabolite acrolein triggers ferroptosis (Fe²⁺-driven lipid peroxidation) in bladder urothelium, creating a plausible theoretical role for Dexrazoxane as an iron chelator to suppress this pathway — though the current standard protectant remains mesna.
Clinical Trial Evidence
Currently no related clinical trials registered for Dexrazoxane in sclerosing cholangitis.
Literature Evidence
Currently no related literature available for Dexrazoxane in sclerosing cholangitis.
Taiwan Market Information
Dexrazoxane is currently not marketed in Taiwan, with no registered product authorizations on file.
| Item | Status |
|---|---|
| Market Status | Not Marketed |
| Number of Authorizations | 0 |
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The sclerosing cholangitis prediction is generated by AI inference alone (L5 evidence), with zero supporting clinical trials or literature; the theoretical connection through iron chelation and oxidative stress is indirect, unvalidated in biliary tissue, and insufficient to justify any translational investment at this stage.
To proceed, the following is needed:
- Regulatory data (Blocking): Obtain the Taiwan TFDA SmPC for Dexrazoxane to extract full warnings, contraindications, and prescribing restrictions — currently the most critical data gap preventing safety evaluation
- MOA data: Complete DrugBank mechanism of action entry to formally verify indication–mechanism compatibility
- Preclinical evidence for PSC: In vitro or animal studies of iron chelation in bile duct injury models before any clinical hypothesis can be formed
- If pivoting to cystitis (Rank 10, the mechanistically superior candidate): Design a head-to-head preclinical study of Dexrazoxane vs. mesna in a cyclophosphamide-induced hemorrhagic cystitis model, specifically measuring ferroptosis markers (GPX4, lipid ROS) to determine whether iron chelation adds protective benefit beyond the established acrolein-scavenging approach
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.